Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

References

• Buxton MJ, Lacey LA, Feagan BG, et al. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn’s Disease Activity Index in Crohn’s disease and measures of utility. Value Health. 2007;10:214–220.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769–2778.
   PubMed Web of Science ®Google Scholar
• Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–165 e2.
   PubMed Web of Science ®Google Scholar
• Behzadi P, Behzadi E, Ranjbar R. The incidence and prevalence of Crohn’s disease in global scale. SOJI. 2015;3.
   Google Scholar
• Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol. 2019;114:107–115.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Kaiser LM, TenHave T, et al. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19:599–613.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349–1362.
   PubMed Web of Science ®Google Scholar
• Fumery M, Dulai PS, Meirick P, et al. Systematic review with meta-analysis: recurrence of Crohn’s disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017;45:381–390.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al.; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106.
   PubMed Web of Science ®Google Scholar
• Gomollon F, Dignass A, Annese V, ECCO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.
   PubMed Web of Science ®Google Scholar
• Meyer A, Rudant J, Drouin J, et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study. Ann Intern Med. 2019;170:99–107.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Liberato NL. Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Rev Pharmacoecon Outcomes Res. 2014;14:815–824.
   PubMed Web of Science ®Google Scholar
• Pillai N, Dusheiko M, Burnand B, et al. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500.
   PubMed Web of Science ®Google Scholar
• Smart C, Selinger CP. The cost-effectiveness of infliximab in Crohn’s disease. Expert Rev Pharmacoecon Outcomes Res. 2014;14:589–598.
   PubMed Web of Science ®Google Scholar
• Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess. 2011;15:1–244.
   PubMed Web of Science ®Google Scholar
• Chaikledkaew U, Teerawattananon Y, editors; Thai Working Group on Health Technology Assessment Guidelines in Thailand. Thai health technology accessment guideline. 2 ed. Chulalongkorn University Book Center; 2013.
   Google Scholar
• Thai Working Group on Health Technology Assessment Guidelines in Thailand. Thai Health Technology Accessment Guideline. J Med Assoc Thai. 2008;91:S1–S88.
   PubMedGoogle Scholar
• Gisbert JP, Marin AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016;111:632–647.
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, et al.; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70 e5; quiz e31.
   PubMed Web of Science ®Google Scholar
• Reenaers C, Mary JY, Nachury M, et al.; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission. Clin Gastroenterol Hepatol. 2018;16:234–243 e2.
   PubMed Web of Science ®Google Scholar
• Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265–274.
   PubMed Web of Science ®Google Scholar
• Rerknimitr R, Chalapipat O, Kongkam P, et al. Clinical characteristics of inflammatory bowel disease in Thailand: a 16 years review. J Med Assoc Thai. 2005;88:S129–S33.
   PubMedGoogle Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Buhl S, Steenholdt C, Rasmussen M, et al. Outcomes after primary infliximab treatment failure in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1210–1217.
   PubMed Web of Science ®Google Scholar
• Hendler SA, Cohen BL, Colombel JF, et al. High-dose infliximab therapy in Crohn’s disease: clinical experience, safety, and efficacy. J Crohns Colitis. 2015;9:266–275.
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49–57.
   PubMed Web of Science ®Google Scholar
• Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45:3–13.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Life tables by country: Thailand. World Health organization; 2016 [2018 Oct 18]. Available from: http://apps.who.int/gho/data/view.main.61640?lang=en
   Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–1422.
   PubMed Web of Science ®Google Scholar
• Riewpaiboon A. Standard cost lists for health technology assessment. Nonthaburi: Health Intervention and Technology Assessment Program (HITAP); 2011 [cited 2019 Feb 28]. Available from: http://costingmenu.hitap.net/
   Google Scholar
• Riewpaiboon A. Measurement of costs. J Med Assoc Thai. 2008;91:S28–S37.
   PubMedGoogle Scholar
• Historical Foreign Exchange Rates [Internet]. Bank of Thailand; 2017 [cited 2019 Aug 1]. Available from: https://www.bot.or.th
   Google Scholar
• Consumer Price index (CPI) of Thailand, Economic and Trade Indices Database (ETID) [Internet]. Bureau of Trade and Economic Indices, Ministry of Commerce; 2017 [cited 2019 May 16]. Available from: http://www.price.moc.go.th
   Google Scholar
• Pattanaphesaj J. Health-related quality of life measure (EQ-5D-5L): measurement property testing and its preference-based score in Thai population [dissertation]. Mahidol University; 2014.
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP; 2006.
   Google Scholar
• Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai. 2008;91 Suppl 2 :S59–S65.
   PubMedGoogle Scholar
• Saito S, Shimizu U, Nan Z, et al. A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease. Health. 2014;06:107–114.
   Google Scholar
• Vasudevan A, Gibson PR, Van Langenberg DR. Systematic review: cost-effective strategies of optimizing anti-tumor necrosis and immunomodulators in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:1462–1473.
   PubMed Web of Science ®Google Scholar
• Rencz F, Gulacsi L, Pentek M, et al. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017;17:597–606.
   PubMed Web of Science ®Google Scholar
• Vasudevan A, Ip F, Liew D, et al. The Cost-effectiveness of initial immunomodulators or infliximab using modern optimization strategies for Crohn’s disease in the biosimilar era. Inflamm Bowel Dis. 2020;26:369–379.
   PubMed Web of Science ®Google Scholar
• Drummond M, Barbieri M, Cook J, et al., editors. Transferability of economic evaluations across jurisdictions. International Society for Pharmacoeconomic and Outcomes Research (ISPOR) – 13th International Meeting; 2008.
   Google Scholar
• Health intervention and technology assessment in support of universal health coverage. Ninth plenary meeting. Sixty-Seventh World Health Assembly; 2014 May 24.
   Google Scholar